About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights

By: via GlobeNewswire

Exton, Pennsylvania, Aug. 28, 2025 (GLOBE NEWSWIRE) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S. ophthalmologists, including retina specialists, sheds light on urgent, unmet needs across eight ophthalmic conditions and spotlights the most promising pipeline therapies set to transform patient care.  

Despite a growing arsenal of pharmacologic treatments, ophthalmologists report too many patients remain without optimal control of their disease. In neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), nearly half of treated patients still fail to achieve adequate disease control. For glaucoma, the challenge is even greater as nearly 81% of patients continue to struggle with dosing complexities and limited efficacy. In geographic atrophy (GA), only one-fifth of patients are receiving prescription therapy, and fewer than half of those is considered well-managed. Uveitic macular edema (UME) tells a similar story: while over half of patients are currently treated, more than one in four are still receiving suboptimal care. Across these conditions, physicians point to the same unmet need priorities—greater efficacy, improved safety, and sustained, long-term disease stability.  

Amid this demanding landscape, ophthalmologists are turning their attention to the pipeline and new therapies in development for various conditions. The report spotlights twenty-four pipeline products garnering varying levels of anticipation. The full breadth of pipeline products include:  

AbbVie/REGENXBIO’s ABBV-RGX-314, 4DMT’s 4D-150, Kodiak Sciences’ tarcocimab tedromer and tabirafusp tedromer, Roche’s vamikibart, Boehringer Ingelheim’s BI 764524, Merck’s Restoret, Adverum’s Ixo-vec, EyePoint Pharmaceuticals’ EYP-1901, Outlook Therapeutics’ ONS-5010, Ocular Therapeutix’s OTX-TKI, J&J’s JNJ-1887 and AAV-RPGR, Aviceda Therapeutics’ AVD-104, Annexon’s ANX007, Belite Bio’s LBS-008, Genentech’s RG6501, Regeneron’s pozelimab, cemdisiran, Beacon Therapeutics’ AGTC-501, Alkeus Pharmaceuticals’ ALK-001, Ascidian Therapeutics’ ACDN-01, Perfuse Therapeutics’ PER-001, Ocuvex Therapeutics’ PDP-716 and Ocular Therapeutix’s PAXTRAVA 

With numerous mechanisms of action in development—including gene therapies, sustained-release implants, and oral or topical options—physicians see potential for a shifting treatment landscape. However, they remain selective and pragmatic in their expectations. Ophthalmologists express cautious optimism, signaling a readiness to adopt new therapies only if they deliver on the promise of durability, accessibility, and meaningful improvements in patient outcomes.  

The latest Special Topix™ report includes responses from 102 U.S.-based retinal specialists and general ophthalmologists, collected between May 6 and June 9, 2025. Participants, who collectively represent a regionally representative and clinically active sample, provided insights on unmet needs, pipeline awareness, product anticipation, and patient candidacy across key ophthalmic indications—including nAMD, DME, GA, DR, Glaucoma, Stargardt and UME. As innovation accelerates and emerging therapies reshape expectations, Spherix will continue to monitor evolving sentiment and provide forward-looking intelligence to inform product strategy, market entry planning, and physician engagement initiatives. 

Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. 

About Spherix Global Insights 

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. 

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. 

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. 

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn. 

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com 

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and analysis addressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. 


Bob Shewbrooks, Ophthalmology Franchise Head
Spherix Global Insights
4848794284
bob.shewbrooks@spherixglobalinsights.com

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.